Cardiac shock-wave therapy in the treatment of coronary artery disease: systematic review and meta-analysis

Greta Burneikaitė1,2,7*, Evgeny Shkolnik3,4, Jelena Čelutkienė1,2*, Gitana Zuozienė1,2, Irena Butkvičienė1,2, Birutė Petrauskiene1,2, Pranas Šerpytis1,2, Aleksandras Laucevičius1,5 and Amir Lerman6

Abstract

Aim: To systematically review currently available cardiac shock-wave therapy (CSWT) studies in humans and perform meta-analysis regarding anti-anginal efficacy of CSWT.

Methods: The Cochrane Controlled Trials Register, Medline, Medscape, Research Gate, Science Direct, and Web of Science databases were explored. In total 39 studies evaluating the efficacy of CSWT in patients with stable angina were identified including single arm, non- and randomized trials. Information on study design, subject’s characteristics, clinical data and endpoints were obtained. Assessment of publication risk of bias was performed and heterogeneity across the studies was calculated by using random effects model.

Results: Totally, 1189 patients were included in 39 reviewed studies, with 1006 patients treated with CSWT. The largest patient sample of single arm study consisted of 111 patients. All selected studies demonstrated significant improvement in subjective measures of angina symptoms and/or quality of life, in the majority of studies left ventricular function and myocardial perfusion improved. In 12 controlled studies with 483 patients included (183 controls) angina class, Seattle Angina Questionnaire (SAQ) score, nitrates consumption were significantly improved after the treatment. In 593 participants across 22 studies the exercise capacity was significantly improved after CSWT, as compared with the baseline values (in meta-analysis standardized mean difference SMD = −0.74; 95% CI, −0.97 to −0.5; p < 0.001).

Conclusions: Systematic review of CSWT studies in stable coronary artery disease (CAD) demonstrated consistent improvement of clinical variables. Meta-analysis showed a moderate improvement of exercise capacity. Overall, CSWT is a promising non-invasive option for patients with end-stage CAD, but evidence is limited to small sample single-center studies. Multi-center adequately powered randomised double blind studies are warranted.

Keywords: Cardiac shock wave therapy, coronary artery disease, stable angina pectoris, refractory angina

Background
A substantial number of patients suffer from disabling angina despite having undergone invasive treatment methods and continuation on optimal medical treatment (OMT) [1]. Such condition is defined as a refractory angina (RFA) [2]. In many cases, stable coronary artery disease (CAD) becomes too diffuse and extensive to be treated by traditional revascularization methods. The annual mortality rate of RFA in recent studies is in the range of 3–4% [3, 4].

Several new alternative treatment methods of RFA are being investigated. A number of studies showed that transmyocardial [5] and percutaneous myocardial laser revascularization [6, 7], spinal cord stimulation [8] and stem cell therapy [9–11] may reduce angina symptoms and improve exercise capacity, myocardial perfusion and function. Nevertheless, these treatment modalities are invasive, quite expensive or still at a preclinical stage.

Enhanced external counter-pulsation is a non-invasive option suggested for CAD patients. However, the recent studies were inconclusive and found no or small differences...
between test and control groups with respect to change in angina or exercise duration [12, 13].

Ultrasound-guided cardiac shock wave (SW) therapy is another promising non-invasive modality in patients with stable CAD. Experimental studies showed that SW might induce shear stress to endothelial cells and produce complex cascade of short- and long-term reactions leading to angiogenesis [14, 15]. The observed immediate increase in blood flow due to local vasodilation and the formation of new capillaries in the treated tissue [16–18] has led to its application in cardiovascular medicine. Since 1999 [19], cardiac shock-wave therapy (CSWT) as a tool for the management of RFA has been investigated in a considerable number of clinical studies.

Our aim was to systematically review and analyse currently available data from CSWT studies in humans and perform meta-analysis regarding efficacy of CSWT on exercise capacity.

Materials and methods
Inclusion criteria, search strategy, methods of data collection and analysis were elaborated in a protocol.

Materials and methods
Inclusion criteria, search strategy, methods of data collection and analysis were elaborated in a protocol.

Data sources
We searched for articles evaluating the efficacy of CSWT in CAD patients from the following medical bibliographic databases: Cochrane Controlled Trials Register, Medline, Medscape, Research Gate, Science Direct, Web of Science (from 1999 to April of 2016), and Google Web. Publications were selected by pre-defined criteria and reviewed by two authors (GB, ES) following PRISMA statement [20]. Disagreements were discussed with other author (JC). The search terms included coronary artery disease, ischemic heart disease, refractory angina treatment, stable angina treatment combined with extracorporeal cardiac shock wave therapy, myocardial shock wave therapy, extracorporeal myocardial revascularisation. We also searched for references in review articles and abstracts.

Study selection criteria
In order to be included, trials had to assess the treatment with CSWT of CAD patients, written in English. Selected studies included patients with stable CAD proven by coronary angiography or computed tomography angiography, not amenable to revascularization, angina class II-IV (Canadian Cardiology Society, CCS), despite OMT, and

---

**Fig. 1** Study flow diagram
documented stress induced myocardial ischemia. Trials investigating combination of CSWT with stem cell therapy were not included.

Data extraction
Information on 1) study design (including study type, method of randomization and blinding of patients, study personnel and outcome assessors), 2) sample size and patients characteristics (including age, sex), 3) intervention strategies (including treatments schedule, follow up duration), 4) outcome measures (including short-acting nitrates consumption per week, CCS angina class and New York Heart Association [NYHA] functional class, Seattle Angina Questionnaire (SAQ) scores, and parameters of the functional tests as exercise duration, workload, global and regional left ventricular [LV] function, myocardial perfusion) were extracted into Microsoft Excel (Microsoft, Seattle, Wash., USA) spread sheets.

Statistical analysis
Variables were presented as mean value ± standard deviation (SD) for continuous data with normal distribution and as median with interquartile range (IQR: Q1, Q3) for data not normally distributed, whereas categorical variables were expressed as number (%).

Assessment of risk of bias randomized trials was performed in accordance with the Cochrane Collaboration tool [21] and was based on information on concealment

| Table 1 PRISMA checklist | Number | Checklist item | Reported on page # |
|--------------------------|--------|----------------|--------------------|
| TITLE                    | 1      | Identify the report as a systematic review, meta-analysis, or both. | 1                 |
| ABSTRACT                 | 2      | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2                 |
| INTRODUCTION             | 3      | Describe the rationale for the review in the context of what is already known. | 3                 |
| Objectives               | 4      | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 3                 |
| METHODS                  | 5      | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 3                 |
| Eligibility criteria     | 6      | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4                 |
| Information sources      | 7      | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4                 |
| Search                   | 8      | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4                 |
| Study selection          | 9      | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4                 |
| Data collection process  | 10     | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4                 |
| Data items               | 11     | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 4                 |
| Risk of bias in individual studies | 12    | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 4–5               |
| Summary measures         | 13     | State the principal summary measures (e.g., risk ratio, difference in means). | Table 2, 4–5     |
| Synthesis of results     | 14     | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis. | 4–5               |
Table 2  Common characteristics of selected human studies of cardiac shock wave therapy

| Author (year) | Study population | Stress test, used to detect myocardial ischemia | Patients, Total control (n) | Age (years) | Sex, male, n (%) | Follow up, months |
|---------------|------------------|-----------------------------------------------|-----------------------------|-------------|------------------|------------------|
| Non-controlled studies | | | | | | |
| Caspari G. H. et al. (1999) [19] | Stable angina | SPECT | 9/- | 65 ± 7 | nd | 6d |
| Gutersohn A. et al. (2003) [51] | Stable angina | SPECT, ET | 25/- | 66 ± 7.3 | nd | 6d |
| Gutersohn A. et al. (2005) [52] | Stable angina | SPECT | 14/- | 66 | nd | 12a |
| Gutersohn A. et al. (2006) [53] | Stable angina | SPECT | 23/- | 66 | nd | 60d |
| Fukumoto Y. et al. (2006) [54] | Stable angina | ET, SPECT | 9/- | 67.8 | 5 (55.5%) | 12d |
| Lyadov K. et al. (2006) [55] | Stable angina | DSE, CPET | 13/- | 59.6 ± 6.9 | 11 (85%) | 1e |
| Naber C. et al. (2007) [56] | Stable angina | SPECT | 25/- | 63.8 ± 8.2 | nd | 3d |
| KhtabAA. et al. (2007) [57] | Stable angina | SPECT | 10/- | nd | nd | 1d |
| Naber C. et al. (2008) [58] | Stable angina | SPECT | 24/- | 63.8 ± 8.2 | 18 (75%) | 3d |
| Takayama T. et al. (2008) [28] | Stable angina | SPECT | 9/- | 67.5 | 17 (100%) | 6d |
| Wang Y. et al. (2010) [59] | Stable angina | DSE, SPECT | 16/- | 71 ± 5.6 | 12 (80%) | 12d |
| Faber L. et al. (2010) [60] | Stable angina | PET, CPET | 16/- | 66 ± 10 | nd | 1d |
| Vainer J. et al. (2010) [61] | Stable angina | ET, SPECT | 22/- | 69 ± 7 | 18 (81.8%) | 4d |
| Vasyuk Y. A. et al. (2010) [25] | Ischemic HF | DSE, SPECT | 24/- | 63.3 ± 6.1 | 20 (83.3%) | 6d |
| Alunni G. et al. (2011) [62] | Stable angina | SPECT | 16/- | 68 ± 9 | 40 (80%) | 4d |
| Vainer J. et al. (2012) [63] | Stable angina | SPECT | 50/- | nd | nd | 6d |
| Alunni G. et al. (2013) [64] | Stable angina | SPECT | 25/- | nd | nd | 6d |
| Gabrusenko S.A. et al. (2013) [29] | Stable angina | SPECT | 17/- | 67.4 ± 8.6 | 14 (82.4%) | 1e |
| Zuoziene G. et al. (2013) [65] | Stable angina | DSE, SPECT | 40/- | 67.7 ± 7 | 30 (75%) | 3d |
| Prinz C. et al. (2013) [66] | Stable angina | ET, PET | 43/- | 67 ± 10 | nd | 1d |
| Cassar A. et al. (2014) [27] | Stable angina | ET, SPECT | 15/- | 65.0 ± 12.1 | 13 (86.7) | 4d |
| Faber L. et al. (2014) [67] | Stable angina | PET | 47/- | 67 ± 10 | nd | 1,5d |
| Prasad M. et al. (2015) [68] | Stable angina | SPECT, ET | 111/- | 62.9 ± 10.9 | 98 (83.7) | 3–6e |
| Kaller M. et al. (2015) [49] | Stable angina | PET, ET | 21/- | 65 ± 10 | 13 (61.9%) | 1.5–2e |
| Cai HY et al. (2015) [30] | Stable angina | ET | 26/- | 63 ± 10 | 23 (88.5%) | 4d |
| Liu BY et al. (2015) [69] | Stable angina | SPECT | 11/- | nd | nd | 12d |
| Vainer J. et al. (2016) [70] | Stable angina | ET, SPECT | 33/- | 69.7 ± 8 | 27 (82%) | 4d |
| Non-randomized, controlled studies | | | | | | |
| Kikuchi Y. et al. (2010) [31] | Stable angina | CPET | 8/8 | 70 ± 3 | 5 (62.5%) | 3d |
| Kazmi W.H. et al. (2012) [71] | Stable angina | SPECT | 86/43 | 57.7 ± 10.5 | 73 (84.5%) | 6d |
| Alunni G. et al. (2014) [72] | Stable angina | SPECT | 72/29 | 70 ± 5.3 | 60 (83.3%) | 6d |
| Nirala S. et al. (2016) [73] | Stable angina | ET, DSE | 52/11 | 63.4 ± 10.8 | 43 (82.7%) | 72d |
| Randomized, controlled studies | | | | | | |
| Peng Y.Z. et al. (2012) [26] | Ischemic HF | SPECT | 50/nd | nd | nd | 1d |
| Wang Y. et al. (2012) [24] | Stable angina | DSE, SPECT | 55/14 | 64.1 ± 9.8 | 47 (85%) | 12e |
| Zhao L. et al. (2015) [74] | Stable angina | SPECT, ET | 87/27 | 66.8 ± 8.4 | 68 (78%) | 12e |
| Randomized, placebo controlled studies | | | | | | |
| Schmid J.P. et al. (2006) [75] | Stable angina | SPECT | 15/8 | 68 ± 8 | 14 (60%) | 3d |
| Yang P. et al. (2012) [76] | Stable angina | SPECT | 45/20 | 67 ± 8.3 | 36 (80%) | 3e |
| Leibowitz D. et al. (2012) [77] | Stable angina | ET, SPECT | 28/10 | 63.3 ± 9.2 | 24 (85.7%) | 3d |
| Schmid J.P. et al. (2013) [78] | Stable angina | CPET | 21/10 | 68 ± 8.3 | 19 (90.5%) | 3d |
| Yang P. et al. (2013) [79] | Stable angina | SPECT | 25/11 | 65.1 ± 8.5 | 18 (72%) | 6d |

Continuous variables were expressed as mean value ± standard deviation (SD), whereas categorical variables were expressed as percentages.

ET  ECG Exercise test, CPET cardiopulmonary exercise test, DSE dobutamine stress echocardiography, PET positron emission tomography, SPECT single photon emission computed tomography; nd = no data; *double blind; †single blind; ‡ double blind, placebo controlled, crossover design; § time after the end of treatment (treatment ends at 9th treatment week); ‖ time from the treatment initiation.
of allocation and random sequence generation, blinding of participants and personnel, incomplete outcome data and selective reporting. For risk of bias assessments the low/unclear/high scale was used.

The effect sizes used in each study are presented as standardized mean difference (SMD) with 95% confidence interval (CI) to allow for combination of different measurements of exercise capacity. In line with Cohen's classification [22], effect sizes were divided into trivial (Cohen's d ≤0.2), small (<0.5), moderate (<0.8), and large (>0.8).

Heterogeneity was assessed by using the chi-square test for heterogeneity and the I² statistic to determine the proportion of variation attributable to heterogeneity among studies. Values of I² considered as low (<25%), moderate (25–50%) and high (>50%) heterogeneity. Meta-analysis results are presented as forest plots. Random effects model according to Der Simonian-Laird was used to verify the significant evidence of heterogeneity between the results of studies. Publication bias was estimated by drawing funnel plot. The analysis was performed using RevMan 5.3 software (Copenhagen, The Nordic Cochrane Centre) [23].

Results
Study characteristics and patient population
From 590 identified publications after exclusion of irrelevant, experimental, animal and non-English studies 39 studies were selected for review following the PRISMA statement [20] (Fig. 1, Table 1); their common characteristics are summarized in Table 2.

In total, 1189 patients were included with 1006 patients treated with CSWT (483 patients underwent CSWT in controlled studies), 183 patients entered control groups. The mean age of patients was 66 ± 6.7 years, 80.8% were men. Study sample size was from 8 to 111 patients; duration of follow up lasted from 1 to 72 months.

No procedure related adverse events and good treatment tolerance were reported.

Studies did not include patients with acute coronary syndromes at least 3 months before enrolment, recent revascularization and thrombus in the left ventricle.

In most studies the treatment protocol consisted of nine sessions conducted over a 9-week period with three treatment series performed on the 1st, 5th and 9th week. Shock waves were applied to targeted area of myocardial ischemia detected by imaging stress tests. Wang showed that a modified regimen of nine treatment sessions within 1 month had similar therapeutic effect, as compared to the standard treatment protocol [24]; only a standard treatment group from this study was included in meta-analysis in order to reduce possible heterogeneity.

Risk of bias and quality assessment of controlled studies is shown in Table 3.

Cardiac shock wave therapy effect on clinical variables
All selected studies demonstrated positive effect of CSWT on clinical variables (results of controlled studies are shown in Table 4). In CSWT patients CCS angina scale (31 studies) and NYHA class (13 studies) have reduced by 1 (1, 1) and 1 (0, 1), respectively, compared with the baseline values. The frequency of weekly nitroglycerine use declined from 40 to 75% (in 16 related studies).

Meta-analysis of cardiac shock wave therapy effect on exercise capacity
Two studies investigating ischemic heart failure population were excluded from meta-analysis [25, 26].

From remaining 37 studies only 22 studies provided data suitable to be included in meta-analysis to evaluate the impact of CSWT on the parameters of exercise Table 3 Quality and risk of bias assessment for randomized studies

|                     | Wang Y. 2012 [24] | Zhao L. 2015 [74] | Yang P. 2012 [76] | Leibowitz D. 2012 [77] | Schmid J.P. 2013 [78] | Yang P. 2013 [79] |
|---------------------|------------------|------------------|------------------|----------------------|----------------------|------------------|
| Random sequence generation | high risk       | low risk         | high risk         | high risk             | high risk             | high risk         |
| Allocation concealment           | high risk       | high risk         | high risk         | high risk             | high risk             | high risk         |
| Blinding of participants          | high risk       | low risk          | high risk         | low risk              | low risk              | low risk          |
| Blinding of personnel who provide CSWT treatment | high risk    | high risk         | high risk         | high risk             | high risk             | high risk         |
| Blinding of outcome assessment      | unclear risk    | high risk         | high risk         | high risk             | high risk             | high risk         |
| Incomplete outcome data            | high risk       | high risk         | low risk          | high risk             | high risk             | low risk          |
| Selective reporting               | low risk        | low risk          | low risk          | low risk              | low risk              | low risk          |
| Blinding of CWST procedure         | high risk       | low risk          | high risk         | low risk              | low risk              | high risk         |
| Endpoints were based on sample size calculation | high risk    | high risk         | high risk         | high risk             | high risk             | high risk         |
| Complete testing in both groups     | low risk        | low risk          | low risk          | low risk              | low risk              | low risk          |

CSWT cardiac shock wave therapy
tolerance (mean and standard deviation or standard error of mean values, both baseline and post procedure), (Fig. 2, Table 5).

Across 22 contributing studies (596 participants) the exercise capacity was significantly improved after CSWT, as compared with the baseline values (SMD = −0.74; 95% CI, −0.97 to −0.5; p < 0.001, I² = 70%, Fig. 2); mean follow up period made 8 months (range 1–72 months).

In order to explain heterogeneity, we performed sensitivity analysis by removing from analysis one of the studies at a time. Overall effect changed to −0.61, 95% CI (−0.78 to −0.44), p < 0.001 when excluding study of Zhao L. et al. (2015) and to −0.77, 95% CI (−1.01 to −0.52), p < 0.001 when excluding study of Prinz C. et al (2013).

Funnel plot analysis was performed in order to evaluate publication bias (Fig. 3). The funnel plot graph was asymmetrical and three outliers were identified representing studies of Caspari, Gutersohn and Zhao group. Without these studies heterogeneity decreased to I² = 0%, p = 0.57 with SMD = −0.54; 95% CI, −0.66 to −0.42; p < 0.001.

Interestingly, in uncontrolled studies treatment effect was smaller than in controlled studies (SMD -0.59 (−0.81, −0.36) vs −0.93 (−1.44, −0.42)).

---

**Table 4** Effect of cardiac shock wave therapy in human controlled studies: clinical and quality of life parameters

| Study            | Type of treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|------------------|------------------|----------|----------------|----------|----------------|----------|----------------|----------|----------------|
| P. Yang 2013 [79]| Test group (N=14)| CCS      | Nitroglycerine | NYHA class| Seattle questionnaire |
|                  |                  | 2.0 (1.0, 3.0) | 2.0 (0.0, 3.0) | 2.0 (1.0, 2.0) | 73.5 (60.5, 81.0) |
|                  |                  | 1.0 (1.0, 2.0)* | 1.0 (0.0, 2.0) | 1.0 (1.0, 1.0)* | 80.0 (74.5, 88.0)* |
| Placebo group (N=11) |                  | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 1.0 (1.0, 2.0) | 73.0 (63.0, 80.0) |
|                  |                  | 2.0 (1.0, 2.0) | 2.0 (0.0, 2.0) | 2.0 (1.0, 2.0) | 78.0 (69.0, 85.0) |
| Y. Wang 2012 [24]| I group (standard treatment) (N=20) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 2 (1, 2) | 1 (0, 2) | 1.5 (1, 3) | 64.9±11.72 |
|                  |                  | 1 (1, 1)* | 0 (0, 1) | 1 (1, 1) | 75.0±10.45* |
| II group (modified treatment) (N=21) |                  | 3 (2, 3) | 2 (0, 3) | 2 (1, 2.5) | 67.9±13.0 |
|                  |                  | 2 (1, 2) | 0 (0, 1) | 1 (1, 1) | 76.1±12.28 |
| Control group (N=14) |                  | 2 (2, 3) | 1 (0, 4) | 2 (1, 3) | 63.2±11.89 |
|                  |                  | 2 (1, 2.3) | 0 (0, 2) | 1 (1, 2.3) | 60.1±12.82 |
| P. Yang 2012 [76]| Test group (N=25) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 2.7±0.46 | 2.35±0.86 | 2.16±0.69 | 65.96±11.78 |
| Placebo group (N=20) |                  | 1.46±0.58* | 1.0±0.73* | 1.48±0.65* | 76.4±11.78* |
| S. Nirala 2016 [73]| Test group (N=41) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 2.2±0.85 | 1.34±1.35 | 1.85±0.96 | 66.3±12.34 |
| Control group (N=11) |                  | 1.14±0.57 | 0.21±0.82 | 1.04±0.49** | 79.92±25.14** |
|                  |                  | 1.81±0.75 | 1.36±1.62 | 1.36±0.67 | 84±7.61 |
|                  |                  | 2.18±0.75 | 2.1±1.18 | 2.09±0.94 | 72.7±12.33 |
| Y. Kikuchi 2010 [31]| Test group (N=8) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 3.0 | 4.0 | - | - |
| Placebo group (N=8) |                  | 2.25* | 1.0* | - | - |
|                  |                  | 2.75 | 4.0 | - | - |
| W.H. Kazmi 2012 [71]| Test group (N=43) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 2.63±0.7 | - | 2.48±0.6 | - |
| Control group (N=43) |                  | 1.95±0.8** | - | 1.95±0.5** | - |
|                  |                  | 2.63±0.7 | - | 2.48±0.6 | - |
| G. Alunni 2014 [72]| Test group (N=43) | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment | Baseline | Post treatment |
|                  |                  | 2.67±0.75 | 26(60.5%) | 2.51±0.74 | - |
| Control group (N=29) |                  | 1.33±0.57** | 9 (20%)* | 1.23±0.42** | - |
|                  |                  | 2.52±0.78 | 18 (41%)* | 2.32±0.79 | - |
|                  |                  | 1.92±0.69 | 13 (44%)* | 1.73±0.59 | - |

CCS Canadian Cardiovascular Society Angina Class, nitroglycerine consumption is expressed as number of tablets per day, NYHA New York Heart Association class, *= p<0.05 compared to baseline, ** = p<0.001 compared to baseline
Cardiac shock wave therapy effect on left ventricular function

Figures 4 and 5 demonstrate changes of rest left ventricular (LV) function by echocardiography and magnetic resonance imaging (MRI), respectively. Changes of LV end diastolic diameter are shown in Fig. 6. Seven studies demonstrated significant LV function improvement due to CSWT, while in eight studies no statistically significant changes were found.

Cardiac shock wave therapy effect on myocardial perfusion

During SPECT significant improvement of myocardial perfusion was demonstrated in 27 of 32 studies, during PET in two of four studies. Beneficial changes of myocardial perfusion were associated with increase of LVEF in seven of 13 studies with modest effect of 3.58% (2.0, 4.57). Cassar et al. [27] compared segments that were treated with CSW and those that were not, and found that after 4 months of follow-up the progression of ischemic burden of untreated segments was significantly greater.

Cardiac shock wave therapy effect on angiogenesis markers

Angiogenesis markers were assessed in four studies. Increased VEGF concentration was revealed after CSWT [28–30]. Kikuchi et al. found that the number of circulating progenitor cells (CD 34+/KDR+/c-kit+) in peripheral blood remained unchanged [31]. Cai et al. observed significant increase in the number of circulating progenitor cells (CD45+/CD34+/VEGFR2) in peripheral blood [30].

Generation of shock waves and cardiac shock wave treatment

Shock waves (SW) belong to acoustic waves that can be transmitted through a liquid medium and focused with a precision of several millimetres to any intended treatment area inside the body.

In CAD patients, SW can be delivered to the border of the ischemic area to potentially induce neovascularization from the healthy area to the ischemic zone. Shock waves can be generated by discharge of a high-voltage spark under water or electromagnetic impulse. CSWT is performed using a SW generator system coupled with a cardiac ultrasound imaging system that is traditionally used to target the treatment area with previously documented ischemia (Fig. 7). SW are delivered via a special applicator through the anatomical acoustic window to the treatment area under electrocardiographic R-wave gating. For optimal therapy, the treatment area is divided into target zones corresponding to the size of the focal zone of the SW applicator (Fig. 7).

| Study or Subgroup | before ESFR | after ESFR | Std. Mean Difference | Std. Mean Difference |
|-------------------|------------|------------|----------------------|----------------------|
|                   | Mean | SD  | Total | Mean | SD  | Total | Weight | IV, Random, 95% CI | Year |
| 1.1.1 Main group  |       |     |       |       |     |       |        |                      |      |
| Lyasov K. et al. 2006 | 11.9 | 2.2 | 13    | 14.1 | 2.8 | 13    | 3.9%   | -0.85 [-1.05, -0.40] | 2006 |
| Fukumoto Y. et al. 2006 | 3.8 | 1.6 | 6     | 5.1  | 1.6 | 6     | 2.6%   | -0.75 [-1.17, 0.00] | 2006 |
| Schmidt J.P. et al. 2006 | 98   | 7   | 15    | 115  | 15  | 7     | 7.5%   | -0.73 [-1.18, 0.37] | 2006 |
| Nabier C. et al. 2008 | 66.6 | 33.3 | 24    | 95.8 | 24  | 24    | 4.9%   | -0.98 [-1.59, -0.38] | 2008 |
| Faber L. et al. 2010 | 80   | 45  | 10    | 80   | 45  | 10    | 4.4%   | -0.20 [-0.81, 0.40] | 2010 |
| Vainer J. et al. 2010 | 7.8  | 4   | 11    | 8.5  | 3   | 22    | 5.0%   | -0.19 [-0.78, 0.40] | 2010 |
| Kikuchi Y. et al. 2010 | 44.7 | 18  | 6     | 50.6 | 16  | 8     | 3.2%   | -0.24 [-1.13, 0.65] | 2010 |
| Vainer J. et al. 2012 | 8.2  | 3.2 | 50    | 9.6  | 3.8 | 50    | 9.0%   | -0.40 [-0.79, 0.00] | 2012 |
| Kazmi V.H. et al. 2012 | 12.2 | 7.9 | 43    | 20.1 | 15  | 43    | 5.8%   | 0.63 [-0.07, -0.20] | 2012 |
| Yang P. et al. 2012 | 339.4 | 83.7 | 25    | 427.9 | 63.3 | 25 | 4.9% | -0.18 [-1.78, -0.57] | 2012 |
| Wang Y. et al.(Standard CSWT) 2012 | 344.25 | 106.44 | 20 | 434.25 | 99.7 | 20 | 4.7% | -0.89 [-1.51, -0.20] | 2012 |
| Schmidt J.P. et al. 2013 | 9.1  | 2.9 | 11    | 9.4  | 1.9 | 11    | 3.6%   | -0.09 [-0.62, 0.75] | 2013 |
| Prinzi C. et al. 2013 | 78   | 53  | 43    | 90   | 46  | 43    | 5.9%   | -0.24 [-0.66, 0.18] | 2013 |
| Cassar A. et al. 2014 | 319.8 | 157.2 | 15    | 422.1 | 183.3 | 15 | 4.3% | -0.38 [-1.32, 0.10] | 2014 |
| Cai H.I. et al. 2015 | 360.69 | 116.79 | 20    | 434.15 | 86.29 | 26 | 5.1% | -0.70 [-1.27, -0.14] | 2015 |
| Koller M. et al. 2015 | 93   | 44  | 16    | 101  | 41  | 16    | 4.4%   | -0.18 [-0.68, 0.35] | 2015 |
| Prasad M. et al. 2015 | 252.1 | 51.6 | 111   | 313.5 | 164.3 | 111 | 6.6% | -0.50 [-0.77, -0.24] | 2015 |
| Vainer J. et al. 2018 | 7.4  | 2.8 | 33    | 6.8  | 3.6 | 33    | 2.5%   | -0.43 [-0.92, 0.09] | 2016 |
| Niralta O. 2016 | 336.65 | 120.46 | 52 | 445.8 | 172.41 | 52 | 5.0% | -0.73 [-1.13, -0.33] | 2016 |
| Overall (95% CI) | 541  |      |       | 541  |      |       | 0.00%  | -0.54 [-0.86, -0.22] |      |

Heterogeneity: Tau²=0.00; Chi²=16.36, df=18 (P=0.57); I²=0%
Test for overall effect: Z=8.54 (P<0.00001)

1.1.2 Outliers

| Study or Subgroup | before ESFR | after ESFR | Std. Mean Difference | Std. Mean Difference |
|-------------------|------------|------------|----------------------|----------------------|
| Caspari O. H. et al. 1999 | 58 | 10 | 9 | 111 | 18 | 10 | 2.1% | -2.60 [-4.19, -1.42] | 1999 |
| Oderbhoinch A. et al. 2005 | 70 | 15.3 | 14 | 100 | 16.8 | 14 | 3.5% | -1.91 [-2.71, -0.91] | 2005 |
| Zhao L. et al.(Standard CSWT) 2015 | 343.91 | 85.03 | 32 | 558.41 | 67.87 | 22 | 4.4% | -2.75 [-3.45, -2.05] | 2015 |
| Overall (95% CI) | 55 |       |       | 55 |       |       | 10.6% | -2.44 [-3.09, -1.79] |       |

Heterogeneity: Tau²=0.31; Chi²=2.92, df=2 (P=0.23); I²=32%
Test for overall effect: Z=2.34 (P<0.0001)

| Study or Subgroup | before ESFR | after ESFR | Std. Mean Difference | Std. Mean Difference |
|-------------------|------------|------------|----------------------|----------------------|
| Total (95% CI) | 596 |       |       | 596 |       |       | 100.0% | -0.74 [-0.97, -0.50] |       |

Heterogeneity: Tau²=0.20; Chi²=70.56, df=21 (P<0.00001); I²=70%
Test for overall effect: Z=6.15 (P<0.00001)
Test for subgroup differences: Chi²=31.63, df=1 (P<0.00001); I²=96.8%

Fig. 2 Meta-analysis of overall impact of cardiac shock wave therapy on exercise capacity
Clinical research in intriguing CSWT field continues since 1999, and several new trials are being published every year. The aim of this study was to summarize the results and also to evaluate the quality of currently accumulated evidence on the efficacy of CSWT on CAD treatment. This systematic review expands previously published analysis [32] by including 23 recent studies, and confirms the beneficial effects of CSWT in a larger pooled sample size of patients with stable CAD. The strength of this paper is a systematic character of review, an inclusion in meta-analysis studies with single clinical indication and a uniform treatment protocol, and assessment of bias risk in randomised trials.

In contrast to our study, recently published meta-analysis of Wang and co-authors covered only a limited period of publications, from 2010 to 2014, and included not only English but also Chinese articles [33]. As a result, our work presents the largest contemporary review of human CSWT trials incorporating all the research period.

Like in the previous analyses the majority of detected trials are relatively small, single centre, single arm, some of them insufficiently report methodology and results. In order to avoid substantial heterogeneity and publication bias reported by Wang, we excluded from meta-analysis studies, which targeted at different population of ischemic heart failure, and also non-English articles as potentially producing more beneficial results. Our study focused on the stable CAD patients and confirmed consistent positive anti-anginal effect of CSWT.

Table 5 Effect of cardiac shock wave therapy on the parameters of exercise capacity

| Study (year)            | Study type         | Number of patients who underwent CSWT | Value before CSWT | Value after CSWT | Measurement unit |
|-------------------------|--------------------|---------------------------------------|-------------------|------------------|-----------------|
| Caspari G.H. et al. (1999) [19] | Single arm        | 9                                     | 58±18             | 111±18           | Wt               |
| Gutersohn A. et al. (2005) [52] | Single arm        | 14                                    | 70±15.3           | 100±16.8         | Wt               |
| Lyadov K. et al. (2006) [55] | Single arm        | 13                                    | 11.9±2.2          | 14±1.28          | VO₂ ml/kg/min    |
| Fukumoto Y. et al. (2006) [54] | Single arm        | 9                                     | 3.9±1.9           | 5±1.7            |                 |
| Schmid J.P. et al. (2006) [75] | Randomized, Placebo controlled | 7                                     | 98±27             | 115±15           | Wt               |
| Naber C. et al. (2008) [58] | Single arm        | 24                                    | 66.6±33.3         | 95.8±24.5        | Wt               |
| Faber L. et al. (2010) [60] | Single arm        | 16                                    | 80±45             | 90±39            | Wt               |
| Vainer J. et al. (2010) [61] | Single arm        | 22                                    | 7.8±4             | 8.5±3            | Minutes          |
| Kikuchi Y. et al. (2010) [51] | Placebo controlled | 8                                     | 44.7±16.2         | 50.5±16.2        | Wt               |
| Vainer J. et al. (2012) [63] | Single arm        | 50                                    | 8.2±3.2           | 9.6±3.8          | Minutes          |
| Kazmi W.H. et al. (2012) [71] | Controlled        | 43                                    | 12.2±7.8          | 20.1±15.7        | Minutes          |
| Yang P. et al. (2012) [79] | Randomized, Placebo controlled | 25                                    | 339.44±83.3       | 427.9±63.3       | Meters           |
| Wang Y. et al. (2012) [24] | Randomized, controlled | 31                                    | 344.3±106.4       | 434.3±99.7       | Meters           |
| Schmid J.P. et al. (2013) [78] | Randomized, Placebo controlled | 11                                    | 91.2±29.1         | 94.1±35.2        | Wt               |
| Prinz C. et al. (2013) [66] | Single arm        | 43                                    | 78±53             | 90±46            | Wt               |
| Cassar A. et al. (2014) [27] | Single arm        | 15                                    | 319.8±157.2       | 422.1±183.3      | Seconds          |
| Zhao L. et al. (2015) [74] | Randomized, controlled | 32                                    | 343.9±85.0        | 489.4±72.2       | Seconds          |
| Prasad M. et al. (2015) [68] | Single arm        | 111                                   | 252.1±51.6        | 313.5±164.3      | Seconds          |
| Kaller M. et al. (2015) [49] | Single arm        | 16                                    | 93±44             | 101±41           | Wt               |
| Cai HY. et al. (2015) [30] | Single arm        | 26                                    | 360.7±116.8       | 434.2±86.3       | Meters           |
| Nirala S. et al. (2016) [73] | Controlled        | 41                                    | 336.7±120.5       | 445.8±172.4      | Meters           |
| Vainer J. et al. (2016) [70] | Single arm        | 33                                    | 7.4±2.8           | 8.8±3.6          | Minutes          |

All valuables presented as mean ± SD, *valuable presented as mean ± SE, SE calculated into SD using standard formulas; *group with standard CSWT protocol, *Bruce protocol, *modified Bruce protocol.

Discussion

Clinical research in intriguing CSWT field continues since 1999, and several new trials are being published every year. The aim of this study was to summarize the results and also to evaluate the quality of currently accumulated evidence on the efficacy of CSWT on CAD treatment. This systematic review expands previously published analysis [32] by including 23 recent studies, and confirms the beneficial effects of CSWT in a larger pooled sample size of patients with stable CAD. The strength of this paper is a systematic character of review, an inclusion in meta-analysis studies with single clinical indication and a uniform treatment protocol, and assessment of bias risk in randomised trials.

In contrast to our study, recently published meta-analysis of Wang and co-authors covered only a limited period of publications, from 2010 to 2014, and included not only English but also Chinese articles [33]. As a result, our work presents the largest contemporary review of human CSWT trials incorporating all the research period.

Like in the previous analyses the majority of detected trials are relatively small, single centre, single arm, some of them insufficiently report methodology and results. In order to avoid substantial heterogeneity and publication bias reported by Wang, we excluded from meta-analysis studies, which targeted at different population of ischemic heart failure, and also non-English articles as potentially producing more beneficial results. Our study focused on the stable CAD patients and confirmed consistent positive anti-anginal effect of CSWT.

In medical field high-energy extracorporeal shock wave therapy (ESWT) was introduced more than 30 years ago as a treatment option for urinary tract stones [34]. ESWT has changed the treatment of urinary calculi, and even today it remains the primary treatment in most non-complicated cases [35]. ESWT has also been applied in biliary tract [36], pancreatic [37] and salivary stones treatment [38]. Low energy ESWT has regenerative features and has been developed as a treatment standard for a variety of orthopedic and soft tissue diseases [39], including wound healing in diabetic patients [40].
Furthermore, shockwaves have been used for treatment chronic pelvic pain syndrome [41] and erectile dysfunction. The observed immediate increase in blood flow due to local vasodilatation and the formation of new capillaries in the treated tissue [16, 17] has led to one of its more promising application in cardiovascular medicine as a possible treatment for patients with stable angina.

The mechanism of CSWT action is multifactorial. SW induces tissue cavitation, leading to a variety of biochemical effects, including shear stress on cell membranes [42], an increase in nitric oxide synthesis [43–46], an up-regulation of vascular endothelial growth factor (VEGF), [14], acceleration of bone marrow cell differentiation into endothelial cells [47], an increase of the amount of circulating endothelial progenitor cells [15]. Thus, CSWT may enhance angiogenesis, reduce inflammatory response, oxidative stress, cellular apoptosis and fibrosis [14, 47, 48].
It is presumed that these mechanisms demonstrated in experimental settings could be translated into clinical effects of improvement of symptoms and myocardial perfusion in CAD patients.

Our review and meta-analysis show that in the majority of published CSWT studies, nitroglycerine consumption and angina frequency decreases, CCS, SAQ scores and NYHA class improves, myocardial perfusion and exercise capacity increases significantly. Most benefits could be observed as early as in the first month, suggesting the contribution of an early local vasodilating effect of SW. Those beneficial effects persisted during the 1-year of follow up, probably related to angiogenesis and other tissue reactions [49, 50].

Total exercise capacity is one of the most important variables used to assess efficacy of any anti-anginal treatment. We evaluated data from randomized clinical studies along with several non-controlled studies of good quality, though certain extent of heterogeneity is not avoided. Our meta-analysis of 596 participants suggests at least a moderate improving effect of CSWT on exercise tolerance.

However, most of the studies included in the review and meta-analysis are single-centre and uncontrolled, making the likelihood of bias towards larger intervention effect substantial. Different methodological quality, inadequate design or unbalanced analysis compels cautious interpretation of the real CSWT effect. Moreover, Wang assessment of methodology confirms our findings that quality of published controlled trials methodology was low [33]. The majority of the randomised studies were evaluated as having high risk if bias in terms of attribution, sample size calculation, blinding of participants and outcome assessment.
Despite very well tolerance, virtually absence of side effects, considerable symptomatic effect and non-invasive nature of CSWT it has not been widely put into practice. This may be associated with the need of special average cost equipment, particular skills of ultrasound scanning and CSWT application, and with the significant time consumption for the whole therapy course as well. Therefore, CSWT can be considered not as a substitutive but as an adjunct therapy in case of limited efficacy of optimal medical treatment.

It seems that the tentative phase of this novel treatment lasted enough, and still there is a lack of high quality evidence. This warrants to perform adequately powered double blind, randomized, placebo controlled study in patients with CAD. Currently appropriately designed multicentre study is ongoing with the aim to confirm the additional improvement of exercise tolerance due to CSWT (NCT02339454).

Conclusions

Systematic review of CSWT studies in stable CAD demonstrated a clinically significant improvement of clinical variables including angina class and quality of life, as well as positive changes in LV function and perfusion. Meta-analysis showed moderate improvement in exercise capacity. Overall, CSWT is a potentially effective new non-invasive option for patients with CAD, but evidence is limited to small low/moderate quality single-centre studies. Multicentre adequately powered rando-mised double blind studies are warranted.

Acknowledgements

Not applicable.

Funding

No funding.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Author’s contributions

GB participated in conception and design creation, collection and interpretation of data, drafting the manuscript. ES participated in conception and design creation, collection and interpretation of data, drafting the manuscript and revising it critically for important intellectual content and final approval of the manuscript submission. JC participated in analysis and interpretation of data, drafting the manuscript and revising it critically for important intellectual content and final approval of the manuscript submission. All authors read and approved the final manuscript.

Competing interests

GB has received investigator fees from Sanofi and Janssen Research; has received travel fee from Servier; has received research support from Medispec (applicants for study NCT02339454); ES has received consulting fee and research support from Medispec (applicants for study NCT02339454); has received speaker fee from Servier, GE Healthcare; has received investigator fees from Servier and Bayer. JC is a member of advisory board for Novartis; has received investigator fees from Amgen and Servier; has received research support from Medispec (applicants for study NCT02339454); GZ has received travel fee from Servier; has received research support from Medispec for Cardiac Shock wave study. IB has received investigator fee from Bioventrix. BP is a member of steering committee for Novartis and Janssen Research; has received speaker fees from Remedica, Astra Zeneca, Pfizer, Bayer and Beohringer -Ingelheim. PS has no competing interest. AL is a member of steering committee for Servier and Sanofi; has received research support from Medispec for Cardiac Shock wave study. AL has no competing interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 2 Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania. 3 Moscow State University of Medicine and Dentistry, Moscow, Russia. 4 Yale-New Haven Health Bridgeport Hospital, Connecticut, United States of America. 5 Centre of Innovative Medicine, Vilnius, Lithuania. 6 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America. 7 Room No A311, Santariskiu str. 2, 08661 Vilnius, Lithuania.

Received: 17 February 2017 Accepted: 30 March 2017

Published online: 12 April 2017

References

1. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010;75:886–91.
2. Mcgillion M, Arthur H, Cook A, Carroll SL, Victor JC, Lallier PL, et al. Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines. Can J Cardiol. 2012;28:520–41.
3. Henry TD. A new option for the “no-option” patient with refractory angina? Catheter Cardiovasc Interv. 2009;74:395–7.
4. Henry TD, Satran D, Hodges JS, Johnson RK, Poulou AW, Campbell AR, et al. Long-term survival in patients with refractory angina. Eur Heart J. 2013;34:2683–8.
5. Briones E, Lalcalc’ JR, Marin I. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2009;1, CD003712.
6. Oesterle SN, Sanborn TA, Ali N, Resar J, Ramee SR, Heuser R, et al. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomized trial. Potential class improvement from intramyocardial channels. Lancet. 2000;356:1705–10.
7. Salem M, Rotavazi S, Nordrehaug JE. Long-term results following percutaneous myocardial laser therapy. Coron Artery Dis. 2006;17:385–90.
8. Taylor RS, De Vries J, Buecher E, Dejongste MJ. Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials. BMC Cardiovasc Disord. 2009;9:13.

9. Van Ramshorst J, Bax JJ, Si B, Dibbets-Schneider P, Roos SD, Stolkel MP, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomised controlled trial. JAMA. 2009;301:1997–2004.

10. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Döbert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009–17.

11. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intra coronary autologous bone marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141–8.

12. Loh PH, Cleland JG, Louis AA, Kennard ED, Cook JF, Caplin JL, et al. Enhanced external counterpulsation in the treatment of chronic refractory angina: A long-term follow-up outcome from the international enhanced external counterpulsation patient registry. Circ Cardiol. 2008;3:119–64.

13. Kumar A, Aronow WS, Vadnerkar A, Sindhu P, Mittal S, Kasliwal RR, et al. Effect of enhanced external counterpulsation on clinical symptoms, quality of life, 6-min walking distance, and echocardiographic measurements of left ventricular systolic and diastolic function after 35 days of treatment and at 1-year follow up in 47 patients with chronic refractory angina pectoris. Am J Ther. 2009;16:116–8.

14. Nishida T, Shimokawa H, Oi K, Tatami T, Uwatsu K, Ake K, et al. Extracorporeal shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110:3055–61.

15. Peng YZ, Guo T, Yang P, Yang HW, Zhou P, Wang Y, et al. Effects of Shock Wave Stimulation for Treatment of Chronic Refractory Angina Pectoris Patients post-bypass surgery. Eur Heart J. 2008;29:200.

16. Young SR, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16:261–9.

17. Wang CJ, Huang HY, Pai CH. Shock wave–enhanced neovascularization at the tendon-bone junction: an experiment in dogs. J Foot Ankle Surg. 2002;41:16–22.

18. Song J, Q M, Kaul S, Price RJ. Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound. Circulation. 2002;106:1550–5.

19. Caspary GH, Erbel R. Revascularization with extracorporeal shock wave therapy: first clinical results. Circulation. 1999;100 Suppl 1884–9.

20. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7), e1000097. doi:10.1371/journal.pmed.1000097.

21. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman A, on behalf of the Cochrane Collaboration. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.

22. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Lawrence Erlbaum; 1988. p. 567.

23. 2014 Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. http://community.cochrane.org/tools/review-production-tools/revman-5about.

24. Wang Y, Guo T, Ma T, Cai H, Tao S, Peng Y, et al. A modified regimen of extracorporeal shock wave therapy for treatment of coronary artery disease. Cardiovasc Ultrasound. 2012;10:35.

25. Vassy J, Hadzegova A, Shkolnik E, Kopeleva M, Honye J, Chiku M, et al. Initial clinical experience with extracorporeal shock wave therapy in treatment of ischemic heart failure. Congest Heart Fail. 2010;16:226–30.

26. Peng YZ, Guo T, Yang P, Yang HW, Zhou P, Wang Y, et al. Effects of extracorporeal shock wave therapy in patients with ischemic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:141–6.

27. Cascar A, Prasad M, Rodriguez-Porcel M, Reeder GS, Kara D, DeMaria AN, et al. Safety and efficacy of extracorporeal shock wave myocardial revascularization therapy for refractory angina pectoris. Mayo Clin Proc. 2014;89:346–54.

28. Takayama T, Saito S, Hirayama A, Honjy J, Chiku M, Yoda T, et al. Investigation into effectiveness of Shock Wave treatment for Angina Pectoris patients post-bypass surgery. Eur Heart J. 2008;29:200.
endstage CAD patients with refractory angina. Presented at the 6th Annual Scientific Meeting of the Japanese Circulation Society 2005.

53. Gutersohn A, Caspari G, Ebel R. Short and long term clinical improvement in patients with refractory angina using Cardiac Shock Wave Therapy (CSWT). Presented at the ACC, 2006.

54. Fukumoto Y, Ito A, Uwatoki T, Matoba T, Kishi T, Takeshita A, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis. 2006;17(1):63–70.

55. Lyadov K, Uvarov A. Cardiac shock-wave therapy: First Experience. Presented at the 6th Mediterranean congress of PRM. 2006;181–2.

56. Naber C, Ebralidze T, Lammers S, Hakim G, Ebel R. Non invasive cardiac angiogenesis shock wave therapy increases perfusion and exercise tolerance in endstage CAD patients. Eur J Heart Fail. 2007;9:71.

57. Khattab A, Brodersen B, Schuermann-Kuchenbrandt D, Beurich H, Tölz R, Geist V, et al. Extracorporeal cardiac shock wave therapy: First experience in the everyday practice for treatment of chronic refractory angina pectoris. Int J Cardiol. 2007;121(1):84–5.

58. Naber C, Lammers S, Lind T, Müller N, Hakim G, Ebel R. Safety and efficacy of extracorporeal low energy shockwave application for the treatment of refractory angina pectoris and myocardial ischemia in patients with end-stage coronary artery disease. Medispec. 2008;1–16.

59. Wang Y, Guo T, Cai HY, Ma TK, Tao SM, Sun S, et al. Cardiac shock wave therapy reduces angina and improves myocardial function in patients with refractory coronary artery disease. Clin Cardiol. 2010;33:693–9.

60. Faber L, Lindner O, Prinz C, Fricke E, Hering D, Burchert W, et al. Echocardiography guided extracorporeal shock wave therapy for refractory angina improves regional myocardial blood flow as assessed by PET imaging. J Am Coll Cardiol. 2010;55(10A):A120.

61. Vainer J, Habets J, Lousberg A, Brans B, Schalla S, Wattenberger J. Cardiac shockwave therapy in patients with end-stage coronary artery disease and chronic refractory angina pectoris – mid term results. Eur Heart J. 2010;31(Abstract Supplement):198.

62. Alunni G, D’Amico M, Meynet L, Andriani M, Giraud E, Giorgi M, et al. A new treatment for patients with refractory angina: extracorporeal shockwave myocardial revascularization. Eur Heart J. 2011;32(Abstract Supplement):S75.

63. Vainer J, Habets J, De Pont C, Lousberg A, Schalla S, Brans B, et al. Extracorporeal shockwave myocardial revascularization therapy (ESWR): an alternative for patients with end-stage coronary artery disease and chronic refractory angina pectoris? Eur Heart J. 2012;33(Abstract Supplement):782.

64. Alunni G, Meynet L, D’Amico M, Garonne P, Checco L, Marra S. Extracorporeal shockwave myocardial revascularization: a promising therapy for refractory angina. Cardiology. 2013;126 Suppl 2:S90.

65. Zuoziene G. Evaluation of myocardium revascularization by cardiac shock wave therapy applying multimodal image analysis. Summary of doctoral dissertation, Vilnius University, 2013.

66. Prinz C, Faber L, Lindner O, Bogunovic N, Hering D, Burchert D, et al. Echocardiography guided extracorporeal shock wave therapy for refractory angina improves regional myocardial blood flow as assessed by PET imaging. Eur Heart J. 2013;34 suppl 1:4007.

67. Faber L, Prinz C, Lindner O, Bogunovic N, Hering D, Burchert D, et al. Echocardiography guided extracorporeal shock wave therapy for refractory angina improves regional left ventricular function along with myocardial blood flow. Eur Heart J. 2014;435(Abstract Supplement):658.

68. Prasad M, Wan Ahmad WA, Sulkmawan R, Magsombo EB, Cassar A, Vinshetok J, et al. Extracorporeal shockwave myocardial therapy is efficacious in improving symptoms in patients with refractory angina pectoris – a multicenter study. Coron Artery Dis. 2015;26:194–200.

69. Liu BY, Li WC, Zhang RS, Chen CX, Yao ZM, He Q. Application of extracorporeal cardiac shock wave therapy in treating coronary heart disease in the elderly. J Am Geriatr Soc. 2015;63:5408.

70. Vainer J, Habets JHM, Schalla S, Lousberg AHP, dePont CDJM, Voo SA, et al. Cardiac shockwave therapy in patients with chronic refractory angina pectoris. Neth Heart J. 2016;24:343–9.

71. Kazmi WH, Rashied S, Ahmed S, Saadat M, Altaf S, Samad A. Noninvasive therapy for the management of patients with advanced coronary artery disease. Coron Artery Dis. 2012;23:549–54.

72. Alunni G, Marra S, Meynet L, D’Amico M, Elisa P, Fanelli A, et al. The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angina. Cardiovasc Revasc Med. 2015;166–11.